The global autism spectrum disorder (ASD) treatment market size was surpassed at USD 1.88 billion in 2021 and is expected to hit around USD 3.5 billion by 2030, growing at a CAGR of 7.15% from 2022 to 2030.
The global autism spectrum disorder (ASD) treatment market size was surpassed at USD 1.88 billion in 2021 and is expected to hit around USD 3.5 billion by 2030, growing at a CAGR of 7.15% from 2022 to 2030.
The autism spectrum disorder (ASD) treatment market is witnessing growth due to the rising burden of the disease. Recently, in March 2022, the updated report of the World Health Organization estimates about 1 in 100 children are suffering from ASD worldwide. According to an October 2021 article, the prevalence of ASD in the U.S. was 1.7% and 1.8% in children aged 4 and 8 years respectively. In addition, the prevalence in Europe ranged between 0.38% to 1.55%. Thus, the current evidence demonstrates the global increase in the prevalence of autism spectrum disorder over the past years.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39768
Autism Spectrum Disorder treatment involves anticonvulsants, antipsychotics, antidepressants, and other drugs that treat symptoms of the disorder. However, currently, there are no treatment options for ASD in the market. Therefore, research and development for better treatment options are offering remunerative opportunities for market growth. For example, in May 2022, FDA granted fast-track designation to Curemark’s CM-AT indicated for ASD in 3-8 years old children. Moreover, in November 2021, Indian researchers developed the 6BIO compound, which has shown potential in improving daily activities in the pre-clinical investigation of patients with an autism spectrum disorder.
Scope of The Report
|
Report Coverage |
Details |
|
Market Size in 2021 |
USD 1.88 billion |
|
Revenue Forecast by 2030 |
USD 3.5 billion |
|
Growth rate from 2022 to 2030 |
CAGR of 7.15% |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segmentation |
Type, Drug Class, Distribution Channel, Region |
|
Companies Covered |
Curemark LLC, Bristol-Myers Squibb, Merck & Co., Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Otsuka Pharmaceutical, Yamo Pharmaceuticals, F. Hoffmann-La Roche Ltd., and Axial Therapeutics amongst others |
The autism spectrum disorder market has been segmented based on drug class as follows:
- Anti-convulsants
- SSRIs
- Anti-psychotics
- Stimulants
- Others
Furthermore, the marketplace is witnessing strong public and private support through investments and funding for research and development. For instance, The Autism Impact Fund announced a capital investment in Yamo Pharmaceuticals, LLC to support phase 2 clinical studies of L1-79, indicated for ASD in November 2021. In addition, Axial Therapeutics successfully raised USD 37 million in Series C funding for AB-2004 drug candidates’ phase 2 clinical trials in children with autism in October 2021.
The space reported a significant impact of the COVID-19 pandemic which is accelerating the market growth. According to the “Coping with autism during lockdown period of the COVID-19 pandemic” published article, during the pandemic ASD patients witnessed accelerated behavioral issues and trouble in coping with mental well-being.
Strategic initiatives such as partnerships, collaborations and investment by key market players are accelerating the market growth. For instance, in July 2022, Sangamo Therapeutics and Novartis AG announced a partnership for developing Zinc Finger technology targeting genes therapies for neurological disorders such as ASD.
Market Drivers & Restraints
DRIVERS
The factors like the growing occurrence of autism in patients along with increasing awareness in people with developed possibilities of examining children boost the market growth globally. The augmenting research and development activities for providing efficient therapies, surging investments, and funds from the government, and growing organizing programs creating awareness in people are driving the ASD market growth. The advancements in technology in improving the healthcare of the patient along with modernization in the medical sector stimulate the market growth during the forecast period.
RESTRAINTS
Shortage of professionals
Factors that limit the autism spectrum treatment market growth are the absence of experienced professionals to examine the ASD. Also, the time and efficiency required for caring and treating the patients that result in obstacles in the market.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39768
Key Market Trends
Autistic Disorder Segment is Expected to Hold a Major Market Share in the Autism Spectrum Disorders Treatment Market
By type, the autistic disorders segment is expected to hold a significant market share attributing to the factors such as increasing research and development as well as the initiatives undertaken by the market players and government. People with autistic disorder usually have significant language delays, social and communication challenges, and unusual behaviors and interests, and people with autistic disorder also have an intellectual disability.
In November 2021, a group of Indian researchers developed a compound called “6BIO” that can provide a better method to treat Autism Spectrum Disorder (ASD). They have determined the potency of the compound in a pre-clinical mice model. This is the first compound that has been proved in pre-clinical evaluation to have the potential for improving daily activities like learning and recollecting new tasks in patients with ASD/ Intellectual disability (ID).
In addition, in October 2021, Axial Therapeutics obtained funding for a Phase II autism trial with USD 37 million Series C to further work on neurological diseases.
Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Key Players
- Curemark LLC
- Bristol-Myers Squibb
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Otsuka Pharmaceutical
- Yamo Pharmaceuticals
- F. Hoffmann-La Roche Ltd.
- Axial Therapeutics
- others
Market Segmentation
- By Type
- Autistic Disorder
- Asperger's Syndrome
- Others
- By Drug Class
- Anti-convulsants
- SSRIs
- Anti-psychotics
- Stimulants
- Others
- By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39768
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/